<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795274</url>
  </required_header>
  <id_info>
    <org_study_id>PHOENIX-01</org_study_id>
    <nct_id>NCT01795274</nct_id>
  </id_info>
  <brief_title>Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial</brief_title>
  <acronym>PHOENIX-01</acronym>
  <official_title>Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The physical and biological properties of the carbon ion beam promise to improve the&#xD;
      therapeutic ratio in patients with pancreatic cancer: Due to the inverted dose profile dose&#xD;
      deposition in the entry channel of the beam leads to sparing of normal tissue; the Bragg peak&#xD;
      can be directed into the defined target volume, and the sharp dose fall-off thereafter again&#xD;
      spares normal tissue behind the target volume. The higher RBE of carbon ions, which has been&#xD;
      shown also for pancreatic cancer cell lines in the preclinical setting, is likely to&#xD;
      contribute to an increase in local control, and perhaps in OS. Early data from Japanese&#xD;
      centers have shown convincing results. The PHOENIX-01 trial is the first trial to evaluate&#xD;
      actively delivered carbon ion beams in patients with locally advanced pancreatic cancer&#xD;
      within a dose-escalation strategy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Administrative barriers&#xD;
  </why_stopped>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity of carbon ion radiotherapy observed within 3 months of study treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Acute toxicity of carbon ion radiotherapy observed within 3 months of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>imaging response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Carbon Ion Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion Radiotherapy</intervention_name>
    <description>Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E</description>
    <arm_group_label>Carbon Ion Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Patients meeting all of the following criteria will be considered for admission to the&#xD;
        trial:&#xD;
&#xD;
          -  histologically confirmed locally advanced pancreatic cancer or imaging defined&#xD;
             pancreatic cancer combined with elevated CA-19-9&#xD;
&#xD;
          -  macroscopic tumor after biopsy&#xD;
&#xD;
          -  age ≥ 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score &gt;=60&#xD;
&#xD;
          -  For women with childbearing potential, (and men) adequate contraception (sexual&#xD;
             abstinence, estrogen- or gestagen containing contraceptive medication etc.)&#xD;
&#xD;
          -  Female participants: No pregnancy present (pregnancy test required)&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients presenting with any of the following criteria will not be included in the trial:&#xD;
&#xD;
          -  distant metastases&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  previous radiotherapy of the abdomen&#xD;
&#xD;
          -  Patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment&#xD;
             interfering with study therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in another clinical study or observation period of competing trials,&#xD;
             respectively&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Jürgen Debus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

